CA2389134C - Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection - Google Patents

Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection Download PDF

Info

Publication number: CA2389134C
Authority: CA; Canada
Prior art keywords: less; housing; time; electromagnetic field; treatment
Prior art date: 1999-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002389134A

Other languages

English (en)

Other versions

CA2389134A1 (fr

Inventor

Luis Canedo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-27

Filing date

2000-08-22

Publication date

2006-05-16

2000-08-22 Application filed by Individual filed Critical Individual

2001-03-08 Publication of CA2389134A1 publication Critical patent/CA2389134A1/fr

2006-05-16 Application granted granted Critical

2006-05-16 Publication of CA2389134C publication Critical patent/CA2389134C/fr

2020-08-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000002193 Pain Diseases 0.000 title abstract description 62
230000036407 pain Effects 0.000 title abstract description 62
206010030113 Oedema Diseases 0.000 title abstract description 51
230000003902 lesion Effects 0.000 title abstract description 51
238000000034 method Methods 0.000 title abstract description 42
208000015181 infectious disease Diseases 0.000 title abstract description 20
230000036961 partial effect Effects 0.000 title abstract description 18
230000002638 denervation Effects 0.000 title abstract description 14
230000008081 blood perfusion Effects 0.000 title abstract description 12
206010061218 Inflammation Diseases 0.000 title abstract description 9
238000011282 treatment Methods 0.000 title description 151
230000004054 inflammatory process Effects 0.000 title description 8
230000005672 electromagnetic field Effects 0.000 claims abstract description 138
230000003068 static effect Effects 0.000 claims abstract description 53
239000000696 magnetic material Substances 0.000 claims description 25
241000282414 Homo sapiens Species 0.000 claims description 16
239000002023 wood Substances 0.000 claims description 13
230000007246 mechanism Effects 0.000 claims description 12
230000004044 response Effects 0.000 claims description 8
210000005036 nerve Anatomy 0.000 abstract description 14
230000037314 wound repair Effects 0.000 abstract description 8
230000002491 angiogenic effect Effects 0.000 abstract description 5
230000012010 growth Effects 0.000 abstract description 5
230000000202 analgesic effect Effects 0.000 abstract description 2
230000003501 anti-edematous effect Effects 0.000 abstract description 2
230000002188 osteogenic effect Effects 0.000 abstract description 2
230000000982 vasogenic effect Effects 0.000 abstract description 2
208000025865 Ulcer Diseases 0.000 description 86
231100000397 ulcer Toxicity 0.000 description 84
206010052428 Wound Diseases 0.000 description 63
208000027418 Wounds and injury Diseases 0.000 description 62
208000005230 Leg Ulcer Diseases 0.000 description 37
230000001684 chronic effect Effects 0.000 description 34
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 34
230000000638 stimulation Effects 0.000 description 34
230000000694 effects Effects 0.000 description 30
206010040943 Skin Ulcer Diseases 0.000 description 23
210000002414 leg Anatomy 0.000 description 22
210000001519 tissue Anatomy 0.000 description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
230000002829 reductive effect Effects 0.000 description 21
201000002282 venous insufficiency Diseases 0.000 description 21
208000004210 Pressure Ulcer Diseases 0.000 description 20
210000003491 skin Anatomy 0.000 description 20
201000010099 disease Diseases 0.000 description 19
210000004165 myocardium Anatomy 0.000 description 19
208000010392 Bone Fractures Diseases 0.000 description 18
230000001965 increasing effect Effects 0.000 description 17
238000001356 surgical procedure Methods 0.000 description 17
230000037230 mobility Effects 0.000 description 16
238000002560 therapeutic procedure Methods 0.000 description 15
206010051055 Deep vein thrombosis Diseases 0.000 description 14
206010047249 Venous thrombosis Diseases 0.000 description 14
208000037849 arterial hypertension Diseases 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
230000033115 angiogenesis Effects 0.000 description 13
239000008280 blood Substances 0.000 description 13
230000035876 healing Effects 0.000 description 13
210000004369 blood Anatomy 0.000 description 12
208000008589 Obesity Diseases 0.000 description 11
238000013461 design Methods 0.000 description 11
206010012601 diabetes mellitus Diseases 0.000 description 11
210000003414 extremity Anatomy 0.000 description 11
230000004907 flux Effects 0.000 description 11
210000001126 granulation tissue Anatomy 0.000 description 11
230000001976 improved effect Effects 0.000 description 11
235000020824 obesity Nutrition 0.000 description 11
206010063560 Excessive granulation tissue Diseases 0.000 description 10
238000012360 testing method Methods 0.000 description 10
206010046996 Varicose vein Diseases 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
210000003141 lower extremity Anatomy 0.000 description 9
230000001354 painful effect Effects 0.000 description 9
206010039073 rheumatoid arthritis Diseases 0.000 description 9
230000035882 stress Effects 0.000 description 9
208000027185 varicose disease Diseases 0.000 description 9
230000004862 vasculogenesis Effects 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 8
208000002847 Surgical Wound Diseases 0.000 description 8
206010000891 acute myocardial infarction Diseases 0.000 description 8
201000006408 generalized atherosclerosis Diseases 0.000 description 8
200000000007 Arterial disease Diseases 0.000 description 7
206010028851 Necrosis Diseases 0.000 description 7
210000000988 bone and bone Anatomy 0.000 description 7
210000002216 heart Anatomy 0.000 description 7
230000000977 initiatory effect Effects 0.000 description 7
208000014674 injury Diseases 0.000 description 7
230000017074 necrotic cell death Effects 0.000 description 7
230000008569 process Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
230000008733 trauma Effects 0.000 description 7
206010011985 Decubitus ulcer Diseases 0.000 description 6
206010017076 Fracture Diseases 0.000 description 6
208000031481 Pathologic Constriction Diseases 0.000 description 6
230000003276 anti-hypertensive effect Effects 0.000 description 6
238000000940 electromagnetic therapy Methods 0.000 description 6
210000002683 foot Anatomy 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
230000036262 stenosis Effects 0.000 description 6
208000037804 stenosis Diseases 0.000 description 6
230000002792 vascular Effects 0.000 description 6
210000003462 vein Anatomy 0.000 description 6
230000029663 wound healing Effects 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 5
206010020772 Hypertension Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000036541 health Effects 0.000 description 5
210000003205 muscle Anatomy 0.000 description 5
230000003387 muscular Effects 0.000 description 5
238000011458 pharmacological treatment Methods 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
230000008439 repair process Effects 0.000 description 5
230000000250 revascularization Effects 0.000 description 5
206010040882 skin lesion Diseases 0.000 description 5
231100000444 skin lesion Toxicity 0.000 description 5
208000002320 spinal muscular atrophy Diseases 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
206010034576 Peripheral ischaemia Diseases 0.000 description 4
206010072170 Skin wound Diseases 0.000 description 4
238000002399 angioplasty Methods 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
239000003527 fibrinolytic agent Substances 0.000 description 4
230000006872 improvement Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000001087 myotubule Anatomy 0.000 description 4
230000003449 preventive effect Effects 0.000 description 4
210000004116 schwann cell Anatomy 0.000 description 4
230000011664 signaling Effects 0.000 description 4
230000000391 smoking effect Effects 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
210000000689 upper leg Anatomy 0.000 description 4
208000027502 Ankle fracture Diseases 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
206010069729 Collateral circulation Diseases 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
206010033892 Paraplegia Diseases 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
238000009534 blood test Methods 0.000 description 3
235000019994 cava Nutrition 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
210000003127 knee Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000001926 lymphatic effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
235000016709 nutrition Nutrition 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
210000004872 soft tissue Anatomy 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
238000007460 surgical drainage Methods 0.000 description 3
210000002978 thoracic duct Anatomy 0.000 description 3
230000002747 voluntary effect Effects 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
206010020649 Hyperkeratosis Diseases 0.000 description 2
206010021639 Incontinence Diseases 0.000 description 2
206010039509 Scab Diseases 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
208000000558 Varicose Ulcer Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000002266 amputation Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
239000003990 capacitor Substances 0.000 description 2
238000002589 cardiac ventriculography Methods 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000002586 coronary angiography Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
231100000321 erythema Toxicity 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000007256 immune mediated inflammatory response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000007574 infarction Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000036651 mood Effects 0.000 description 2
210000002161 motor neuron Anatomy 0.000 description 2
201000000585 muscular atrophy Diseases 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
235000008935 nutritious Nutrition 0.000 description 2
210000001696 pelvic girdle Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
230000001643 venotonic effect Effects 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000009042 Anterior Wall Myocardial Infarction Diseases 0.000 description 1
101100342994 Arabidopsis thaliana IIL1 gene Proteins 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
208000001308 Fasciculation Diseases 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000003790 Foot Ulcer Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000034819 Mobility Limitation Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
206010056697 Tissue anoxia Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000034790 Twin pregnancy Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000036626 alertness Effects 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000002583 angiography Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
201000009521 anteroseptal myocardial infarction Diseases 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940085393 aspirin 150 mg Drugs 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000001266 bandaging Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
208000034526 bruise Diseases 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000037998 chronic venous disease Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000002567 electromyography Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
230000005021 gait Effects 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
201000002818 limb ischemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000001699 lower leg Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000003102 mental depression Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000020763 muscle atrophy Effects 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000011164 ossification Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000007832 reinnervation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010008 shearing Methods 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
231100000019 skin ulcer Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
210000002465 tibial artery Anatomy 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
208000037997 venous disease Diseases 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Radiology & Medical Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Medicinal Chemistry (AREA)
Magnetic Treatment Devices (AREA)

CA002389134A 1999-08-27 2000-08-22 Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection Expired - Lifetime CA2389134C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15118599P	1999-08-27	1999-08-27
US60/151,185		1999-08-27
PCT/IB2000/001480 WO2001015770A2 (fr)	1999-08-27	2000-08-22	Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection

Publications (2)

Publication Number	Publication Date
CA2389134A1 CA2389134A1 (fr)	2001-03-08
CA2389134C true CA2389134C (fr)	2006-05-16

Family

ID=22537671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002389134A Expired - Lifetime CA2389134C (fr)	1999-08-27	2000-08-22	Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection

Country Status (4)

Country	Link
AU (1)	AU7679300A (fr)
CA (1)	CA2389134C (fr)
TW (1)	TW567078B (fr)
WO (1)	WO2001015770A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6733435B2 (en)	2002-03-08	2004-05-11	Canedo Luis	Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain, edema, inflammation and infection
WO2003080179A1 (fr) *	2002-03-27	2003-10-02	Nippon Sigmax Co., Ltd.	Dispositif de regulation de cytokines, dispositif de traitement et procede de traitement
ATE347919T1 (de) *	2002-05-29	2007-01-15	Richard Dr Markoll	Vorrichtung zur behandlung eines menschlichen körperteils mittels eines elektromagnetischen feldes
GR1004411B (el) *	2002-07-25	2004-01-07		Ηλεκτρονικηασυσκευηαγιααενισχυσηαανοσοποιητικουασυστηματοσαμεαχρησηαμαγνητικωναπεδιωναμεαχαρακτηριστικαααποαπολυδιαυλοαβιομαγνητομετρο
US20070078292A1 (en) *	2005-10-05	2007-04-05	Electromagnetic Resources, Inc.	Electromagnetic fields for systemic effect in therapy
WO2011078645A2 (fr) *	2009-12-21	2011-06-30	Alandra Medical S.A.P.I. De C.V.	Équipement de stimulation électromagnétique pour le traitement systémique sur le bras de plaies chroniques, l'activation de l'angiogenèse et l'augmentation de la perméabilité vasculaire
WO2011078644A2 (fr) *	2009-12-21	2011-06-30	Alandra Medical S.A.P.I. De C.V.	Équipement de stimulation électromagnétique pour le traitement systémique au niveau du thorax de lésions chroniques, l'activation de l'angiogenèse et l'augmentation de la perméabilité vasculaire
US10076384B2 (en)	2013-03-08	2018-09-18	Symple Surgical, Inc.	Balloon catheter apparatus with microwave emitter
EP3334495A4 (fr) *	2015-08-12	2019-05-01	Innoventions Ltd	Système de réparation tissulaire comme la réparation d'un sphincter urinaire et/ou autre, sujet à des fuites
US11364390B2 (en)	2017-02-07	2022-06-21	Santi Tofani	Apparatus for treating pathological cells
EP3744392A4 (fr) *	2018-01-24	2021-09-22	Hefei Institutes of Physical Science, Chinese Academy of Sciences	Procédé de régénération de cartilage, dispositif à impulsions magnétiques et bobine appliquée à un dispositif à impulsions magnétiques
US10967194B2 (en)	2018-05-02	2021-04-06	Shealy-Sorin Wellness, Llc	Pulsed electromagnetic field device and methods of use
KR20230147460A (ko) *	2022-04-14	2023-10-23	서울대학교산학협력단	암 치료용 직류 자기장 발생 장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2021506A1 (fr) *	1989-08-17	1991-02-18	Abraham R. Liboff	Traitement electromagnetique pour les victimes d'accidents cerebro-vasculaires
US5131904A (en) *	1990-05-04	1992-07-21	Richard Markoll	Treatment of arthritis with magnetic field therapy and apparatus therefor
US5314401A (en) *	1991-03-29	1994-05-24	Amei Technologies Inc.	Conformable PEMF transducer
US5752911A (en) *	1995-04-27	1998-05-19	Canedo; Luis E.	Electromagnetic method of treatment of epilepsy and apparatus

2000
- 2000-08-22 CA CA002389134A patent/CA2389134C/fr not_active Expired - Lifetime
- 2000-08-22 WO PCT/IB2000/001480 patent/WO2001015770A2/fr not_active Ceased
- 2000-08-22 AU AU76793/00A patent/AU7679300A/en not_active Abandoned
- 2000-08-22 TW TW89117304A patent/TW567078B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU7679300A (en)	2001-03-26
WO2001015770A3 (fr)	2001-09-27
TW567078B (en)	2003-12-21
WO2001015770A2 (fr)	2001-03-08
CA2389134A1 (fr)	2001-03-08

Legal Events

Date	Code	Title	Description
2002-11-18	EEER	Examination request
2020-10-27	MKEX	Expiry	Effective date: 20200824

Publication	Publication Date	Title
US6733435B2 (en)	2004-05-11	Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain, edema, inflammation and infection
KR101134242B1 (ko)	2012-04-09	생체전기자극, 치료가속화, 통증감소, 또는 병원체탈활화용 장치 및 방법
Kloth et al.	1988	Acceleration of wound healing with high voltage, monophasic, pulsed current
Shupak et al.	2003	Therapeutic uses of pulsed magnetic-field exposure: a review
RU2160130C1 (ru)	2000-12-10	Способ нормализации биологических функций живых тканей и устройство для электромагнитного воздействия на живые ткани
Strauch et al.	2009	Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery
Vodovnik et al.	1992	Treatment of chronic wounds by means of electric and electromagnetic fields part 1 literature review
US20180104505A1 (en)	2018-04-19	Apparatus and method for electromagnetic treatment
CA2389134C (fr)	2006-05-16	Procede electromagnetique permettant de traiter des lesions liees a une perfusion sanguine inadaptee, une denervation partielle, une perte tissulaire, la douleur, un oedeme, une inflammation et infection
EP1741467A1 (fr)	2007-01-10	Appareil electromagnetique de traitement de lesions associees a une perfusion sanguine inadaptee, a une denervation partielle, a une perte de tissu, a une douleur, a un oedeme, a une inflammation ou a une infection
KR20080080483A (ko)	2008-09-04	통합 코일 장치 및 이를 이용하는 방법
Szołtys-Brzezowska et al.	2023	Electrical stimulation in the treatment of pressure injuries: a systematic review of clinical trials
Gogia et al.	1988	Wound management with whirlpool and infrared cold laser treatment: a clinical report
RU2067879C1 (ru)	1996-10-20	Способ воздействия на биологический объект
Ganne et al.	1979	Inferential therapy to promote union of mandibular fractures
RU2152039C1 (ru)	2000-06-27	Биоинженерный способ ремоделирования сосудистой системы мозга
RU2337725C2 (ru)	2008-11-10	Способ лечения повреждения периферического нерва
Ma et al.	2013	Pulsed electromagnetic field treatment in wound healing
Stephens et al.	1979	The use of intra-arterial chemotherapy for treatment of malignant skin neoplasms.
Senejko et al.	2021	Application of Magnetoledtherapy and Magnetostimulation in the Treatment of Chronic Finger Wound After Injury. Case Report.
RU2371217C2 (ru)	2009-10-27	Способ лечения хронического простатита с нарушением половой функции
Nair et al.	0	Products & technology Case reports Products & technology
Belik et al.	2015	Magnetoelectric system for accelerated healing of venous ulcers in diabetic foot syndrome
RU2593356C1 (ru)	2016-08-10	Способ лечения хронического панкреатита с нарушением процессов пищеварения
Pentelényi	0	PULSED MAGNETIC THERAPY